The Prognostic Impact of Circulating Tumour DNA in Melanoma Patients Treated with Systemic Therapies—Beyond <i>BRAF</i> Mutant Detection

The Prognostic Impact of Circulating Tumour DNA in Melanoma Patients Treated with Systemic Therapies—Beyond <i>BRAF</i> Mutant Detection

In this study, we evaluated the predictive value of circulating tumour DNA (ctDNA) to inform therapeutic outcomes in metastatic melanoma patients receiving systemic therapies. We analysed 142 plasma samples from metastatic melanoma patients prior to commencement of systemic therapy: 70 were treated...

Full description

Bibliographic Details
Main Authors: Gabriela Marsavela, Peter A. Johansson, Michelle R. Pereira, Ashleigh C. McEvoy, Anna L. Reid, Cleo Robinson, Lydia Warburton, Muhammad A. Khattak, Tarek M. Meniawy, Benhur Amanuel, Michael Millward, Nicholas K. Hayward, Melanie R. Ziman, Elin S. Gray, Leslie Calapre
Format: Article
Language:English
Published: MDPI AG 2020-12-01
Series:Cancers
Subjects:
circulating tumour DNA (ctDNA)
melanoma
<i>BRAF</i>
response
targeted therapy
immunotherapy
Online Access:https://www.mdpi.com/2072-6694/12/12/3793

Internet

https://www.mdpi.com/2072-6694/12/12/3793

Similar Items